PPARGC1A and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: PGC-1α thus emerges as a potential therapeutic target to treat muscular dystrophies and could be a potential candidate for a multi-pronged therapy in dysferlinopathies.